RECURRENT HIGH GRADE B-CELL LYMPHOMA
Clinical trials for RECURRENT HIGH GRADE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT HIGH GRADE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT HIGH GRADE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to boost immune attack on Hard-to-Treat lymphoma
Disease control Recruiting nowThis study tests whether adding an experimental drug (ST-067) to standard CAR T-cell therapy can improve outcomes for people with large B-cell lymphoma that has returned or not responded to prior treatments. About 33 adults will receive the combination to find the safest dose and…
Matched conditions: RECURRENT HIGH GRADE B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
Engineered immune cells take on HIV-Linked lymphoma in new trial
Disease control Recruiting nowThis phase 1 trial is testing a CAR-T cell therapy (axicabtagene ciloleucel) in 20 adults with HIV and aggressive B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The therapy uses a patient's own immune cells, modified to recognize and attack cancer c…
Matched conditions: RECURRENT HIGH GRADE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: AIDS Malignancy Consortium • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
New drug duo shows promise for Tough-to-Treat lymphoma
Disease control Recruiting nowThis study tests whether combining two targeted drugs—loncastuximab tesirine and mosunetuzumab—can shrink or eliminate tumors in people with diffuse large B-cell lymphoma that has returned or not responded to prior treatment. About 36 adults will receive the drug combination, and…
Matched conditions: RECURRENT HIGH GRADE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
New drug may boost CAR-T success in tough lymphomas
Disease control Recruiting nowThis study tests a drug called odronextamab given before CAR-T cell therapy for people with large B-cell lymphoma that has returned or not responded to treatment. The goal is to see if this approach can keep the cancer under control and help more patients successfully receive CAR…
Matched conditions: RECURRENT HIGH GRADE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 11, 2026 20:48 UTC